Hai-Chuan Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hai-Chuan Yu has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Fang-Chao Tong
School of Pharmacy, Xinxiang Medical University, Xinxiang, China
4 shared publications- Jiao Wu
School of Pharmacy, Xinxiang Medical University, Xinxiang, China
3 shared publications Jiao-Jie Guo
School of Pharmacy, Xinxiang Medical University, Xinxiang, China
3 shared publicationsShuang-Ling Zhang
School of Medical Technology, Henan Key Laboratory of Immunology and Targeted Drugs, Henan Collaborative Innovation Center of Molecular Diagnosis and Laboratory Medicine, Xinxiang Medical University, Xinxiang, China
3 shared publications- Chaokun Li
Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Henan Medical University, Xinxiang, China
2 shared publications - Guomin Shen
Department of hematology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, People's Republic of China; Department of Cell Biology, School of Basic Medical Sciences, Harbin Medical University, Harbin, Heilongjiang, People's Republic of China
2 shared publications
Latest Publications
- 16 March 2026
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 364, 121543
Illuminating the black box of traditional Chinese medicine: The pivotal role of transgenic fluorescent zebrafish
- 16 March 2026
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 364, 121543
Illuminating the black box of traditional Chinese medicine: The pivotal role of transgenic fluorescent zebrafish
- Open Access
- 12 September 2025
- Published by Elsevier in Environment International
- Vol. 203, 109771
Chlorogenic acid counteracts mycophenolate mofetil-induced neurotoxicity in zebrafish and PC12 cells: A potential bioremediation strategy for aquatic pharmaceuticals
- 12 September 2025
- Published by Elsevier in Environment International
- Vol. 203, 109771
Open AccessChlorogenic acid counteracts mycophenolate mofetil-induced neurotoxicity in zebrafish and PC12 cells: A potential bioremediation strategy for aquatic pharmaceuticals
- 10 September 2025
- Published by Elsevier in Fish & Shellfish Immunology
- Vol. 167, 110874
LPS disrupts erythroid-myeloid balance in zebrafish via Jak2/Stat3-Hif1a signaling
- 10 September 2025
- Published by Elsevier in Fish & Shellfish Immunology
- Vol. 167, 110874
LPS disrupts erythroid-myeloid balance in zebrafish via Jak2/Stat3-Hif1a signaling
- 1 January 2025
- Published by SAGE Publications in Antioxidants & Redox Signaling
- Vol. 42 (1-3) , 36-52
Regulation of Erythroid Differentiation via the HIF1α-NFIL3-PIM1 Signaling Axis Under Hypoxia
Erythropoiesis is controlled by several factors including oxygen level under different circumstances. However, the role of hypoxia in erythroid differentiation and the underlying mechanisms are poorly understood. We studied the effect and mechanism of hypoxia on erythroid differentiation of K562 cells and observed the effect of hypoxia on early erythropoiesis of zebrafish. Compared with normal oxygen culture, both hemin-induced erythroid differentiation of K562 cells and the early erythropoiesis of zebrafish were inhibited under hypoxic treatment conditions. Hypoxia-inducible factor 1alpha (HIF1α) plays a major role in the response to hypoxia. Here, we obtained a stable HIF1α knockout K562 cell line using CRISPR/Cas9 technology, and further demonstrated that HIF1α knockout promoted hemin-induced erythroid differentiation of K562 cells under hypoxia. We demonstrated a HIF1-mediated induction of the nuclear factor interleukin-3 regulated (NFIL3) in K562 cells under hypoxia. Interestingly, a gradual decrease in NFIL3 expression was detected during erythroid differentiation of EPO-induced CD34+ hematopoietic stem/progenitor cells (HSPCs) and hemin-induced K562 cells. Notably, erythroid differentiation was inhibited by enforced expression of NFIL3 under normoxia and was promoted by the knockdown of NFIL3 under hypoxia in hemin-treated K562 cells. In addition, a target of NFIL3, serine/threonine kinase PIM1, was obtained by RNA microarray after NFIL3 knockdown. PIM1 can rescue the inhibitory effect of NFIL3 on hemin-induced erythroid differentiation of K562 cells. Our findings demonstrate that the HIF1α-NFIL3-PIM1 signaling axis plays an important role in erythroid differentiation under hypoxia.
- 1 January 2025
- Published by SAGE Publications in Antioxidants & Redox Signaling
- Vol. 42 (1-3) , 36-52
Regulation of Erythroid Differentiation via the HIF1α-NFIL3-PIM1 Signaling Axis Under Hypoxia
Erythropoiesis is controlled by several factors including oxygen level under different circumstances. However, the role of hypoxia in erythroid differentiation and the underlying mechanisms are poorly understood. We studied the effect and mechanism of hypoxia on erythroid differentiation of K562 cells and observed the effect of hypoxia on early erythropoiesis of zebrafish. Compared with normal oxygen culture, both hemin-induced erythroid differentiation of K562 cells and the early erythropoiesis of zebrafish were inhibited under hypoxic treatment conditions. Hypoxia-inducible factor 1alpha (HIF1α) plays a major role in the response to hypoxia. Here, we obtained a stable HIF1α knockout K562 cell line using CRISPR/Cas9 technology, and further demonstrated that HIF1α knockout promoted hemin-induced erythroid differentiation of K562 cells under hypoxia. We demonstrated a HIF1-mediated induction of the nuclear factor interleukin-3 regulated (NFIL3) in K562 cells under hypoxia. Interestingly, a gradual decrease in NFIL3 expression was detected during erythroid differentiation of EPO-induced CD34+ hematopoietic stem/progenitor cells (HSPCs) and hemin-induced K562 cells. Notably, erythroid differentiation was inhibited by enforced expression of NFIL3 under normoxia and was promoted by the knockdown of NFIL3 under hypoxia in hemin-treated K562 cells. In addition, a target of NFIL3, serine/threonine kinase PIM1, was obtained by RNA microarray after NFIL3 knockdown. PIM1 can rescue the inhibitory effect of NFIL3 on hemin-induced erythroid differentiation of K562 cells. Our findings demonstrate that the HIF1α-NFIL3-PIM1 signaling axis plays an important role in erythroid differentiation under hypoxia.
- 15 August 2024
- Published by Elsevier in Phytomedicine
- Vol. 134, 155956
Elucidating hydroxysafflor yellow A's multi-target mechanisms against alcoholic liver disease through integrative pharmacology
- 15 August 2024
- Published by Elsevier in Phytomedicine
- Vol. 134, 155956
Elucidating hydroxysafflor yellow A's multi-target mechanisms against alcoholic liver disease through integrative pharmacology
- Open Access
- 3 February 2022
- Published by Wiley in The FEBS Journal
- Vol. 289 (15) , 4564-4579
Structural features determining the vitamin K epoxide reduction activity in the VKOR family of membrane oxidoreductases
Vitamin K epoxide reductases (VKORs) are a large family of integral membrane enzymes found from bacteria to humans. Human VKOR, specific target of warfarin, has both the epoxide and quinone reductase activity to maintain the vitamin K cycle. Bacterial VKOR homologs, however, are insensitive to warfarin inhibition and are quinone reductases incapable of epoxide reduction. What affords the epoxide reductase activity in human VKOR remains unknown. Here, we show that a representative bacterial VKOR homolog can be converted to an epoxide reductase that is also inhibitable by warfarin. To generate this new activity, we first substituted several regions surrounding the active site of bacterial VKOR by those from human VKOR based on comparison of their crystal structures. Subsequent systematic substitutions narrowed down to merely eight residues, with the addition of a membrane anchor domain, that are responsible for the epoxide reductase activity. Substitutions corresponding to N80 and Y139 in human VKOR provide strong hydrogen bonding interactions to facilitate the epoxide reduction. The rest of six substitutions increase the size and change the shape of the substrate‐binding pocket, and the membrane anchor domain stabilizes this pocket while allowing certain flexibility for optimal binding of the epoxide substrate. Overall, our study reveals the structural features of the epoxide reductase activity carried out by a subset of VKOR family in the membrane environment.
- 3 February 2022
- Published by Wiley in The FEBS Journal
- Vol. 289 (15) , 4564-4579
Open AccessStructural features determining the vitamin K epoxide reduction activity in the VKOR family of membrane oxidoreductases
Vitamin K epoxide reductases (VKORs) are a large family of integral membrane enzymes found from bacteria to humans. Human VKOR, specific target of warfarin, has both the epoxide and quinone reductase activity to maintain the vitamin K cycle. Bacterial VKOR homologs, however, are insensitive to warfarin inhibition and are quinone reductases incapable of epoxide reduction. What affords the epoxide reductase activity in human VKOR remains unknown. Here, we show that a representative bacterial VKOR homolog can be converted to an epoxide reductase that is also inhibitable by warfarin. To generate this new activity, we first substituted several regions surrounding the active site of bacterial VKOR by those from human VKOR based on comparison of their crystal structures. Subsequent systematic substitutions narrowed down to merely eight residues, with the addition of a membrane anchor domain, that are responsible for the epoxide reductase activity. Substitutions corresponding to N80 and Y139 in human VKOR provide strong hydrogen bonding interactions to facilitate the epoxide reduction. The rest of six substitutions increase the size and change the shape of the substrate‐binding pocket, and the membrane anchor domain stabilizes this pocket while allowing certain flexibility for optimal binding of the epoxide substrate. Overall, our study reveals the structural features of the epoxide reductase activity carried out by a subset of VKOR family in the membrane environment.
- Open Access
- 7 August 2020
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (15) , 3659-3667
Characterization of missense mutations in the signal peptide and propeptide of FIX in hemophilia B by a cell-based assay
Many mutations in the signal peptide and propeptide of factor IX (FIX) cause hemophilia B. A FIX variants database reports 28 unique missense mutations in these regions that lead to FIX deficiency, but the underlying mechanism is known only for the mutations on R43 that interfere with propeptide cleavage. It remains unclear how other mutations result in FIX deficiency and why patients carrying the same mutation have different bleeding tendencies. Here, we modify a cell-based reporter assay to characterize the missense mutations in the signal peptide and propeptide of FIX. The results show that the level of secreted conformation-specific reporter (SCSR), which has a functional γ-carboxyglutamate (Gla) domain of FIX, decreases significantly in most mutations. The decreased SCSR level is consistent with FIX deficiency in hemophilia B patients. Moreover, we find that the decrease in the SCSR level is caused by several distinct mechanisms, including interfering with cotranslational translocation into the endoplasmic reticulum, protein secretion, γ-carboxylation of the Gla domain, and cleavage of the signal peptide or propeptide. Importantly, our results also show that the SCSR levels of most signal peptide and propeptide mutations increase with vitamin K concentration, suggesting that the heterogeneity of bleeding tendencies may be related to vitamin K levels in the body. Thus, oral administration of vitamin K may alleviate the severity of bleeding tendencies in patients with missense mutations in the FIX signal peptide and propeptide regions.
- 7 August 2020
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (15) , 3659-3667
Open AccessCharacterization of missense mutations in the signal peptide and propeptide of FIX in hemophilia B by a cell-based assay
Many mutations in the signal peptide and propeptide of factor IX (FIX) cause hemophilia B. A FIX variants database reports 28 unique missense mutations in these regions that lead to FIX deficiency, but the underlying mechanism is known only for the mutations on R43 that interfere with propeptide cleavage. It remains unclear how other mutations result in FIX deficiency and why patients carrying the same mutation have different bleeding tendencies. Here, we modify a cell-based reporter assay to characterize the missense mutations in the signal peptide and propeptide of FIX. The results show that the level of secreted conformation-specific reporter (SCSR), which has a functional γ-carboxyglutamate (Gla) domain of FIX, decreases significantly in most mutations. The decreased SCSR level is consistent with FIX deficiency in hemophilia B patients. Moreover, we find that the decrease in the SCSR level is caused by several distinct mechanisms, including interfering with cotranslational translocation into the endoplasmic reticulum, protein secretion, γ-carboxylation of the Gla domain, and cleavage of the signal peptide or propeptide. Importantly, our results also show that the SCSR levels of most signal peptide and propeptide mutations increase with vitamin K concentration, suggesting that the heterogeneity of bleeding tendencies may be related to vitamin K levels in the body. Thus, oral administration of vitamin K may alleviate the severity of bleeding tendencies in patients with missense mutations in the FIX signal peptide and propeptide regions.